Today, GlaxoSmithKline plc (GSK) announced that it has acquired Swiss vaccines specialist GlycoVaxyn for $190 million. More than two years ago, GSK took a minority stake in the vaccine developer as part of a collaboration to develop new antibacterial conjugate vaccines. And now the company is paying $190 million in …